IFRX on Nasdaq

InflaRx N.V.

InflaRx N.V. is a pharmaceutical preparations company, listed on Nasdaq (IFRX).1

Price unavailable

Last updated Oct 20, 2026.

Overview

29.3KRevenue, fiscal 20252
-45.6MNet income, fiscal 20252

Compare with Inventiva S.A., Nanobiotix S.A. or Morphosys, or pick any stock.

  • TickerIFRX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersP71
  • Incorporated inNetherlands3
  • Business addressWinzerlaer Str. 2, Jena, 2M 077453
  • Filer categoryNon-accelerated filer3

See how the biggest companies compare on our leaderboards

Ann Arbor, Michigan 48103. Our principal executive offices and laboratories are located in Winzerlaer Str. 2, 07745 Jena, Germany, telephone:4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in EUR, the currency the company reports in.

Key numbers, fiscal 2025

-24677.9%Gross margin2
-155582.1%Net margin2
-82.3%Revenue growth, 20252
-109.8%Return on equity2

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue100¢7.3M EUR
  • Interest0¢2.7K EUR
  • Income tax0¢12.3K EUR

Out of 29.3K EUR in revenue.2 The company lost money this year.

Financial statements

Revenue229.3K EUR in 2025−54% since 2023
050.0K EUR100.0K EUR150.0K EUR200.0K EUR2023: 63.1K EUR63.1K EUR20232024: 165.8K EUR165.8K EUR2024+163%2025: 29.3K EUR29.3K EUR2025−82%
Gross profit52-7.2M EUR in 2025−81% since 2018
-40.0M EUR-30.0M EUR-20.0M EUR-10.0M EUR02018: -37.8M EUR-37.8M EUR20182023: -469.2K EUR-469.2K EUR2023−99%2024: -3.2M EUR-3.2M EUR2024+572%2025: -7.2M EUR-7.2M EUR2025+130%
Operating income6-44.9M EUR in 2023−6% since 2021
-60.0M EUR-40.0M EUR-20.0M EUR02021: -47.6M EUR-47.6M EUR20212022: -32.2M EUR-32.2M EUR2022−32%2023: -44.9M EUR-44.9M EUR2023+39%
Net income7896102-45.6M EUR in 2025+53% since 2018
-60.0M EUR-40.0M EUR-20.0M EUR02018: -29.8M EUR-29.8M EUR20182019: -53.3M EUR-53.3M EUR2019+79%2020: -34.0M EUR-34.0M EUR2020−36%2021: -45.6M EUR-45.6M EUR2021+34%2022: -29.5M EUR-29.5M EUR2022−35%2023: -42.7M EUR-42.7M EUR2023+45%2024: -46.1M EUR-46.1M EUR2024+8%2025: -45.6M EUR-45.6M EUR2025−1%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-12-312024-12-312023-12-31
Revenues29.3K EUR165.8K EUR63.1K EUR
Cost of sales-7.3M EUR-3.3M EUR-532.3K EUR
Gross profit-7.2M EUR-3.2M EUR-469.2K EUR
Marketing and sales expenses-4.5M EUR-6.8M EUR-4.0M EUR
Research and development expenses-25.7M EUR-35.4M EUR-41.0M EUR
General and administrative expenses-13.5M EUR-13.0M EUR-12.6M EUR
Other income2.7M EUR5.3M EUR13.2M EUR
Other expenses-14.6K EUR-297 EUR-4.4K EUR
Operating result-48.3M EUR-53.0M EUR-44.9M EUR
Finance income1.8M EUR3.2M EUR3.8M EUR
Finance expenses-39.2K EUR-20.7K EUR-35.6K EUR
Foreign exchange result-4.9M EUR3.7M EUR-1.8M EUR
Other financial result5.7M EUR103.3K EUR313.2K EUR
Income taxes-12.3K EUR-5.2K EUR
Loss for the period-45.6M EUR-46.1M EUR-42.7M EUR
Exchange differences on translation of foreign currency-269.1K EUR58.3K EUR125.1K EUR
TOTAL COMPREHENSIVE LOSS-45.9M EUR-46.0M EUR-42.5M EUR
Weighted average number of shares outstanding (in Shares)67.3M shares58.9M shares54.9M shares
Loss per share (basic) (in Euro per share)-0.68 EUR-0.78 EUR-0.78 EUR
Loss per share (diluted) (in Euro per share)-0.68 EUR-0.78 EUR-0.78 EUR

Compare InflaRx N.V. with another company

Corporate structure

InflaRx N.V. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of InflaRx N.V.

  • Commodore Capital LP Filed SCHEDULE 13G on InflaRx N.V., latest Aug 17, 2026
  • FARALLON CAPITAL MANAGEMENT, L.L.C. Filed SCHEDULE 13G/A on InflaRx N.V., latest Aug 14, 2026
  • MONTANOVA CAPITAL, LLC Filed SCHEDULE 13G/A on InflaRx N.V., latest Aug 14, 2026 (4 filings since Feb 13, 2023)
  • Sirenia Capital Management LP Filed SCHEDULE 13G on InflaRx N.V., latest Aug 14, 2026
  • FMR LLC Filed SCHEDULE 13G on InflaRx N.V., latest Aug 6, 2026
  • Farallon Capital Partners, L.P. Filed SCHEDULE 13G on InflaRx N.V., latest May 14, 2026
  • TCG Crossover GP III, LLC Filed SCHEDULE 13G on InflaRx N.V., latest May 12, 2026
  • TANG CAPITAL PARTNERS LP Filed SC 13G/A on InflaRx N.V., latest Feb 14, 2024 (2 filings since Apr 17, 2023)
  • GREAT POINT PARTNERS LLC Filed SC 13G/A on InflaRx N.V., latest Feb 14, 2022
  • InflaRx N.V. P7

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What InflaRx N.V. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net289.3K EUR2 Dec 31, 2025256.3K EUR2 Dec 31, 2024+12.9%
Operating-lease assets (leased space)861.7K EUR2 Dec 31, 2025758.4K EUR2 Dec 31, 2024+13.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents16.0M EUR2 Dec 31, 202518.4M EUR2 Dec 31, 2024−12.8%

Inventory

ItemLatestA year beforeChange
Inventory, total6.9M EUR2 Dec 31, 202411.4M EUR10 Dec 31, 2023−39.3%
Raw materials82.1K EUR2 Dec 31, 2024423.6K EUR2 Dec 31, 2023−80.6%

Leadership

Who has led InflaRx N.V., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Niels Riedemann2026–now

Chief financial officer

  1. Thomas Taapken2026–now
Board members and other officers (9)

Former names

  • Fireman B.V.Jun 23, 2017 to Nov 8, 20173

Timeline

  1. Mar 18, 2026New chief executive Niels Riedemann becomes CEO12

Calendar

Coming up

  1. Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.16) a share, on Nov 10, 2025.21

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

128 filings to the SEC since October 2021: 5 annual reports, 9 insider forms, 13 large holders, 101 other. The latest 20:

  1. Aug 17, 2026SCHEDULE 13G EDGAR
  2. Aug 14, 2026424B5 425B5 EDGAR
  3. Aug 14, 2026SCHEDULE 13G/A EDGAR
  4. Aug 14, 2026SCHEDULE 13G EDGAR
  5. Aug 14, 2026SCHEDULE 13G/A EDGAR
  6. Aug 12, 2026EFFECT EDGAR
  7. Aug 6, 2026F-3 EDGAR
  8. Aug 6, 2026S-8 EDGAR
  9. Aug 6, 20266-K EDGAR
  10. Aug 6, 2026SCHEDULE 13G EDGAR
  11. Jun 30, 20266-K EDGAR
  12. May 14, 2026SCHEDULE 13G EDGAR
  13. May 12, 2026SCHEDULE 13G EDGAR
  14. May 7, 20266-K EDGAR
  15. May 7, 2026424B5 EDGAR
  16. May 6, 2026424B5 EDGAR
  17. May 6, 20266-K EDGAR
  18. May 6, 20266-K EDGAR
  19. May 4, 20266-K EDGAR
  20. Apr 28, 20266-K EDGAR

The 128 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How InflaRx N.V. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARInflaRx N.V.1
  • CIK0001708688
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company4
  • Incorporated inNetherlands4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressWinzerlaer Str. 2, Jena, 2M 077451
  • Phone49 3641 5081801
  • Shares outstanding72,292,859 shares as of Dec 31, 20254
  • AuditorKPMG AG Wirtschaftsprüfungsgesellschaft, Munich, Germany PCAOB ID 1021; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceJun 23, 20171
  • Filings286 in all: 6-K (151), SC 13G/A (21), SC 13G (17), 424B5 (12), CORRESP (12), UPLOAD (11), 20-F (9), 3 (9)1
    All 27 form types

    EFFECT (5), SCHEDULE 13G (5), DRSLTR (4), F-1/A (4), F-3 (3), S-8 (3), SCHEDULE 13G/A (3), 424B4 (2), DRS (2), DRS/A (2), F-1 (2), SC 13D (2), 20-F/A (1), 8-A12B (1), CERTNAS (1), CT ORDER (1), F-3/A (1), F-3ASR (1), POS EX (1)

  • Latest filingsAnnual report (20-F) Mar 20, 2026

Securities registered for trading

ClassSymbolExchange
Ordinary Shares, nominal value €0.12 per shareIFRXThe Nasdaq Stock Market LLC

From the cover page of the 20-F filed Mar 20, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30